Specifically, we proposed that incorporating a cathepsin B (CatB) cleavage site would enable tumor‐specific intracellular CO release, while introducing a bioorthogonal handle would allow tumor targeting through conjugation to a suitable antibody (Scheme 1). Here, CTSB is linked to neoplasm.